- Home
- KULR vs ANNX Comparison
KULR vs ANNX Comparison
Compare KULR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- ANNX
- Stock Information
- Founded
- KULR 2013
- ANNX 2011
- Country
- KULR United States
- ANNX United States
- Employees
- KULR N/A
- ANNX N/A
- Industry
- KULR Electrical Products
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- ANNX Health Care
- Exchange
- KULR Nasdaq
- ANNX Nasdaq
- Market Cap
- KULR 275.2M
- ANNX 252.3M
- IPO Year
- KULR N/A
- ANNX 2020
- Fundamental
- Price
- KULR $0.84
- ANNX $2.38
- Analyst Decision
- KULR Strong Buy
- ANNX Strong Buy
- Analyst Count
- KULR 2
- ANNX 4
- Target Price
- KULR $5.00
- ANNX $12.50
- AVG Volume (30 Days)
- KULR 18.1M
- ANNX 1.4M
- Earning Date
- KULR 08-11-2025
- ANNX 08-11-2025
- Dividend Yield
- KULR N/A
- ANNX N/A
- EPS Growth
- KULR N/A
- ANNX N/A
- EPS
- KULR N/A
- ANNX N/A
- Revenue
- KULR $11,436,983.00
- ANNX N/A
- Revenue This Year
- KULR $87.77
- ANNX N/A
- Revenue Next Year
- KULR $102.93
- ANNX N/A
- P/E Ratio
- KULR N/A
- ANNX N/A
- Revenue Growth
- KULR 16.47
- ANNX N/A
- 52 Week Low
- KULR $0.20
- ANNX $1.29
- 52 Week High
- KULR $5.49
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- KULR 33.25
- ANNX 54.28
- Support Level
- KULR $0.73
- ANNX $2.26
- Resistance Level
- KULR $1.32
- ANNX $2.81
- Average True Range (ATR)
- KULR 0.10
- ANNX 0.21
- MACD
- KULR -0.04
- ANNX -0.02
- Stochastic Oscillator
- KULR 17.54
- ANNX 45.68
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.